Home World News FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection World News FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 476 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC June 24, 2026 Increased Efficacy of Pembrolizumab or Pembrolizumab-Chemotherapy with Increasing PD-L1 Expression in... April 11, 2022 Dual Inhibition of LAG-3 and PD-1 in Patients with Previously Untreated... January 10, 2022 Singer Surprises 6-Year-Old Fan Who Beat Cancer With Trip To Disney January 10, 2022 Load more HOT NEWS Foodie Friday: Couscous Salad Potential Value of ctDNA NGS-based Analysis of Imatinib Resistant Secondary KIT... Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II... Workout Wednesdays – Chest Exercises Part 2